Objective The efficacy of thymosin alpha 1 (Tai) in patients with chronic hepatitis B still requires confirmation. We, therefore, evaluated the efficacy of therapy in patients with chronic hepatitis B.
Introduction
Chronic hepatitis B is a serious liver disease with significant mortality and morbidity. However,in patients with clearance of hepatitis B virus (HBV)DNA,the prognosis of the disease is generally good (1) (2) (3) (4) . Regardless of some beneficial drugs, such as interferon (IFN), lamivudine and steroid, there are no absolute treatments in chronic hepatitis B at the present time.
Thymosin alpha 1 (Tai), a 28 amino acid thymic polypeptide hormone, is a chemically synthesized immunomodulator (5) . A randomized, controlled study conducted by Chien et al showed that a 26-week course of Tai therapy was effective and safe in patients with chronic hepatitis B compared with placebo or a 52-week course of Tai (6) .
However, a multicentre, randomized, double-blind and placebo-controlled study of 97 patients did not confirm observations of treatment efficacy (7) . Thus, the efficacy of Tai still necessitates confirmation (8, 9) . We, therefore, conducted a randomized, clinical trial of Tai in patients with chronic hepatitis B and examined the independent factors that might influence the response to Tai therapy.
Materials and Methods
Pa tien ts Sixteen Japanese patients were enrolled in this trial from April 1997 to December1999. The patients were randomly assigned to receive one of two dose groups of Tai by the computer generated program designed by a pharmaceutical company (SciClone Japan K.K., Tokyo, Japan). The selection criteria for patients included in the study were as follows: 1) an average ALTincrease greater than the upper normal limits (normal serum ALTlevel is 6-50 IU//) for longer than 6 months, 2) liver biopsy (taken within 6 months before IFN administration) showing histological features of 
Blood tests
Routine biochemical and hematological tests were made at weekly to monthly intervals during treatment and during a follow-up of more than 6 months after the termination of Toti treatment. The remaining serum samples were divided and stored at -80°C until use. HBsAgand HBeAg/HBeAb were determined by EIA (Abbott Diagnostics, Chicago, IL).
HBV-DNA was measured by branched DNAsignal amplification technology (Chiron Corp., Emeryville, CA), and the results were expressed as 106 genomic equivalents (Meq) per milliliter.
The lower limit of the assay was 0.7 Meq/ml. Genotyping of HBVwas performed by an ELISA using monoclonal antibodies for the genotype specific epitopes in the pre S2 region product (10) . Anti-hepatitis C virus antibody was detected by third generation enzyme-linked immunoassay (Ortho Diagnostics Japan, Tokyo, Japan).
Definition of response after Tai therapy and transient acute exacerbation during Tai therapy
Responders were defined as patients whosatisfied the following three items 24 months after the initiation of Tai treat- Patterns of serum ALTbefore, during, and after Tai th erapy Patterns of serum ALTlevels were classified into three types according to the ratio of maximumALTlevel (a) to minimumALTlevel (b). In the constant type, the a/b ratio was 1-3; in the slight fluctuation type, the a/b ratio was 3-6; and in the severe fluctuation type, the a/b ratio was 6 or more. Patterns of serum ALTlevels were assessed every 6 months from 6 months before the initiation of Toci therapy to 6 months after the termination of Toti therapy.
Liver histology
Baseline histological activity (grading) and fibrosis (staging) before Toti therapy were scored semi-quantitatively as previously described (1 1).
Statistical analysis
The Fisher's exact test was used for comparison of group frequencies. Moreover, relative to an identified distribution (Ridit) analysis was used for the patterns of serum ALTbefore, during, and after Toil therapy. A p value of <0.05 by the two-tailed test was considered to indicate a significant difference.
Results

Clinical background
The background characteristics and baseline measurements for each group are summarized in Table 1 . There were no significant differences between the two groups in age, sex, body weight, serum ALT, platelet count, HBV-DNA levels, HBV-genotype, HBeAg and the histopathological diagnosis of biopsied liver specimens prior to Toti therapy.
Efficacy of Tai therapy
The response rate was 37.5% (6/16) 24 months after the initiation of Tai therapy. Due to Fisher's exact test, Tai therapy had a significant effect when, 1) transient acute exacerbation was present (p=0.0029), 2) the serum HBV-DNA level was <100 Meq/ml prior to the commencementof Tai therapy (p=0.0063).
The difference between the low and high dose group was not statistically significant (p=0.608) ( ( Fig. 4) . The serum ALTlevel displayed 822 IU/Z two months after the initiation of Toil. Moreover this patient had marked elevation of serum ALTat six months after end of treatment. After the second marked elevation of serum ALT, the serum level of ALTdecreased to within the normal range with disappearance of HBeAgand HBV-DNA. Case 3 was a 35-year-old male (Fig. 5 ). This patient had a constant pattern of serum ALTbefore, during, and after Toti therapy. He showed positivity of HBeAgand HBV-DNA 24 months after the initiation of Toil therapy.
Clinical safety
No dose adjustment was necessary in patients given Toil. 
Discussion
IFN therapy suppresses chronic HBVinfection (12) (13) (14) (15) (16) , however a sustained response to IFN has proven difficult to attain. In manystudies the clearance rate of HBeAg after daily treatment with IFN for 4 weeks was only 15-25% for HBeAgpositive patients with chronic hepatitis (17) (18) (19) . The HBeAgseroconversion rate is at most 30-40%with larger IFN doses administered for 4 to 6 months. Moreover, patients treated with larger IFN doses often drop out of treatment studies due to IFN-related side effects and high-dose IFN is also very expensive. Thus, IFN therapy for HBeAgpositive chronic hepatitis B entails problems with efficacy, cost, and side effects.
Next, lamivudine therapy has recently been approved for treatment of chronic hepatitis B. However, the HBeAg seroconversion rate is at most 20-30% with lamivudine ad- Moreover, Tai can stimulate natural killer activity (23) . Previous studies on Tai therapy have had conflicting results, some suggesting that Tai therapy was effective for chronic hepatitis B, whereas others found that Tai therapy was not statistically effective. In these studies there were differences in the time of determination of response or not. The later the time to determinate the therapeutic effect in Tai therapy, the better the response rate (6 (6) . Toti has pharmacological actions with modulate T-cell function to promote endogenous IFN-y, interleukin-2 production and to stimulate natural killer activity. The present results seem to indicate that the pharmacological actions of low-dose (0.8 mg) Toti are similar to those of high-dose (1.6 mg) Toti. With respect to side effects, no patients had a significant decrease in the leukocyte count or platelet count. Four patients showed serum ALTlevels of more than 300 IU// during Toti therapy and two of them had serum ALTlevels of greater than 800 IU//. However, no patient had acute hepatic failure, icterus or edema. Therefore, it is critical to carefully monitor patients treated with Toti therapy for possible acute exacerbation. Taken together, as Toti therapy should a moderate efficacy with few side effects, it would thus be a desirable strategy for chronic hepatitis B patients with a low level of serum HBV-DNA. In the present study, we did not examine the antibody of human immunodeficiency virus. However, all patients had a normal lymphocyte count and serum y-globulin level. The results of the present trial showed that: 1) a 24-week course of Toti could be a worthwhile strategy for chronic hepatitis B patients with a serum HBV-DNA level of less than 100 Meq/ml; and 2) patients with transient acute exacerbation during Toti therapy generally respond well.
